Zhejiang Orient Gene Biotech Co., Ltd. (688298.SS)
CNY 29.1
(-2.68%)
CNY 29.1
(-2.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.6 Billion | 2.99 Billion | 5.2 Billion | 1.79 Billion | 54.21 Million | 44.32 Million |
| Net Income | -397.58 Million | 2.09 Billion | 4.94 Billion | 1.68 Billion | 77.5 Million | 63.95 Million |
| Depreciation & Amortization | 183.49 Million | 86.55 Million | 37.3 Million | 7.43 Million | 6.38 Million | 5.48 Million |
| Deferred income taxes | -27.75 Million | -120.78 Million | -24.22 Million | -40.68 Million | -667.15 Thousand | -1.59 Million |
| Stock-based compensation | - | 120.78 Million | 24.22 Million | 40.68 Million | 667.15 Thousand | - |
| Change in working capital | -1.54 Billion | 101.81 Million | 113.54 Million | -12.46 Million | -36.21 Million | -29.95 Million |
| Other non-cash items | 2.09 Billion | 710.11 Million | 112.36 Million | 115 Million | 6.53 Million | 4.84 Million |
| Investing Cash Flow | -2.16 Billion | -2.37 Billion | -321.63 Million | -548.83 Million | -11.73 Million | -18.75 Million |
| Investments in PPE | -996.04 Million | -1.05 Billion | -507.87 Million | -126.93 Million | -11.9 Million | -18.87 Million |
| Acquisitions | -77.7 Million | -184.87 Million | -43.7 Million | 127.02 Million | 168.98 Thousand | 4.76 Million |
| Investment purchases | -471.04 Million | -1.73 Billion | -1.52 Billion | -3.4 Billion | - | - |
| Sales/Maturities of investments | 552.58 Million | 678.68 Million | 1.75 Billion | 2.98 Billion | - | - |
| Other Investing Activities | -1.16 Billion | -77.71 Million | 1.78 Million | -126.93 Million | 0.48 | 124.16 Thousand |
| Financing Cash Flow | 49.53 Million | -698.24 Million | -509.17 Million | 503.29 Million | -60.29 Million | -5.72 Million |
| Debt repayment | -453.5 Million | -50 Million | -6.97 Million | -26.96 Million | -68.5 Million | -72 Million |
| Dividends payments | -336 Million | -742.03 Million | -504.67 Million | -25.28 Million | -33.21 Million | -3.67 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -37.4 Million | 93.78 Million | 2.46 Million | 555.54 Million | 41.42 Million | 69.95 Million |
| Accounts receivables | 210.27 Million | 825.39 Million | -692.05 Million | -640.45 Million | -31.93 Million | -14.39 Million |
| Accounts payables | -1.66 Billion | 172.33 Million | 928.52 Million | 1.04 Billion | 824.43 Thousand | 14.44 Million |
| Inventory | -86.22 Million | -775.13 Million | -98.7 Million | -379.08 Million | -4.44 Million | -28.41 Million |
| Other working capital | -1.69 Billion | -120.78 Million | -24.22 Million | -40.68 Million | -667.15 Thousand | -1.54 Million |
| Cash at beginning of period | 6.59 Billion | 6.09 Billion | 1.8 Billion | 85.34 Million | 102.23 Million | 77.82 Million |
| Cash at end of period | 4.16 Billion | 6.55 Billion | 6.09 Billion | 1.8 Billion | 85.34 Million | 102.23 Million |
| Capital Expenditure | -996.04 Million | -1.05 Billion | -507.87 Million | -126.93 Million | -11.9 Million | -18.87 Million |
| Effect of forex changes on cash | 85.85 Million | 536.64 Million | -75.43 Million | -29.77 Million | 925.15 Thousand | 4.55 Million |
| Net cash flow / Change in cash | -2.43 Billion | 458.62 Million | 4.29 Billion | 1.71 Billion | -16.88 Million | 24.4 Million |
| Free Cash Flow | -2.59 Billion | 1.94 Billion | 4.69 Billion | 1.66 Billion | 42.31 Million | 25.44 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -110.54 Million | -84.25 Million | -67.35 Million | -397.58 Million | -325.19 Million | -107.19 Million |
| Depreciation & Amortization | - | 54.93 Million | 54.93 Million | 183.49 Million | 55.28 Million | -66.2 Million |
| Deferred income taxes | - | - | - | -27.75 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -47.34 Million | - | -1.54 Billion | 124.04 Million | -14.95 Million |
| Other non-cash items | 97.89 Million | 38.31 Million | -137.89 Million | 2.09 Billion | 343.2 Million | -244.27 Million |
| Investing Cash Flow | 606.99 Million | -779.47 Million | -107.34 Million | -2.16 Billion | -1.88 Billion | -68.35 Million |
| Investments in PPE | -117.85 Million | -139.87 Million | -243.92 Million | -996.04 Million | -457.25 Million | -128.74 Million |
| Acquisitions | 55.45 Thousand | -278.58 Million | -43.8 Million | -77.7 Million | -17.21 Million | 28.6 Thousand |
| Investment purchases | -101.02 Million | 229.06 Million | -352.06 Million | -471.04 Million | -313.36 Million | -98.88 Million |
| Sales/Maturities of investments | 175.95 Million | 1.05 Billion | 532.44 Million | 552.58 Million | 83.82 Million | 145.05 Million |
| Other Investing Activities | 649.92 Million | -1.64 Billion | 187.01 Million | -1.16 Billion | -1.18 Billion | 14.2 Million |
| Financing Cash Flow | -66.55 Million | -278.4 Million | -30.02 Million | 49.53 Million | 14.21 Million | -50.31 Million |
| Debt repayment | -48.6 Million | -8.1 Million | -20.4 Million | -453.5 Million | -21.38 Million | -200 Million |
| Dividends payments | -3.51 Million | -3.38 Million | -4.04 Million | -351.13 Million | -39.5 Million | -50.34 Million |
| Common Stock Repurchased | 275 Million | -275 Million | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -14.44 Million | -2.44 Million | -9.62 Million | -37.4 Million | 359.38 Million | 200.02 Million |
| Accounts receivables | - | 60.93 Million | - | 210.27 Million | 210.27 Million | -5.98 Million |
| Accounts payables | - | - | - | -1.66 Billion | - | - |
| Inventory | - | -108.27 Million | - | -86.22 Million | -86.22 Million | -8.97 Million |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 1.46 Billion | 3.46 Billion | 4.16 Billion | 6.59 Billion | 4.87 Billion | 5.43 Billion |
| Cash at end of period | 1.94 Billion | 3.04 Billion | 3.46 Billion | 4.16 Billion | 4.16 Billion | 4.84 Billion |
| Capital Expenditure | -117.85 Million | -139.87 Million | -243.92 Million | -996.04 Million | -457.25 Million | -128.74 Million |
| Effect of forex changes on cash | -23.72 Million | 24.3 Million | 9.31 Million | 85.85 Million | -8.69 Million | -37.24 Million |
| Net cash flow / Change in cash | 481.92 Million | -419.21 Million | -702.85 Million | -2.43 Billion | -714.73 Million | -588.54 Million |
| Free Cash Flow | -130.5 Million | -240.74 Million | -449.17 Million | -2.59 Billion | -494.53 Million | -561.38 Million |
OIBR4
RRKABEL
LLYVA
ABT
IDT
600439